# Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

> **NCT00436605** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00436605
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436605, "Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00436605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*